Magnova 250 mg/31.25 mg Injection
By Magnova
Rx
1 Injection in a Vial

Composition
Cefepime(250mg) + Tazobactum(31.25mg)

Manufacturer - Lupin Ltd
Lupin Ltd, 3rd floor Kalpataru Inspire, Off. W E Highway, Santacruz (East), Mumbai 400 055. India

Expires on or after
October, 2025

liver
When it comes to the safety of using Magnova 250 mg/31.25 mg Injection for individuals with liver disease, it appears to be generally safe based on the limited information. There is no clear indication that adjusting the dose of Magnova 250 mg/31.25 mg Injection is necessary for patients with liver issues. However, it is always recommended to consult with your doctor before using this medication to ensure it is suitable for your specific situation.

kidney
"Caution should be taken in patients with kidney disease when using Magnova 250 mg/31.25 mg Injection. Dosage adjustment may be necessary. Consult your doctor."

alcohol
Caution is advised when consuming alcohol with Magnova 250 mg/31.25 mg Injection. Consult your doctor.

driving
After using Magnova 250 mg/31.25 mg Injection, your vision may be blurred briefly. Avoid driving until your vision returns to normal.

pregnancy
Magnova 250 mg/31.25 mg Injection is considered safe during pregnancy based on animal studies with low risk to the baby, but limited human studies exist.

breastfeeding
Magnova 250 mg/31.25 mg Injection is considered safe for use during breastfeeding. Research indicates that the medication does not pass into breastmilk in substantial quantities and poses no harm to the baby.
Habit Forming | No |
Chemical Class | - |
Therapeutic Class | ANTI INFECTIVES |
Action Class | - |
₹138.35
Inclusive of all taxes
Content verified by

Dr. Abdullah Khan
MBBS - General Medicine
Last update on 01-Oct-2024